BTK inhibition is a potent approach to block IgE‐mediated histamine release in human basophils

BACKGROUND: Recent data suggest that Bruton's tyrosine kinase (BTK) is an emerging therapeutic target in IgE receptor (IgER)‐cross‐linked basophils. METHODS: We examined the effects of four BTK inhibitors (ibrutinib, dasatinib, AVL‐292, and CNX‐774) on IgE‐dependent activation and histamine rel...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Allergy
Autori principali: Smiljkovic, D., Blatt, K., Stefanzl, G., Dorofeeva, Y., Skrabs, C., Focke‐Tejkl, M., Sperr, W. R., Jaeger, U., Valenta, R., Valent, P.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2017
Soggetti:
ORIGINAL ARTICLES
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5655929/
https://ncbi.nlm.nih.gov/pubmed/28328081
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/all.13166
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi